PE20190660A1 - Mutantes de la polimerasa de hbv - Google Patents
Mutantes de la polimerasa de hbvInfo
- Publication number
- PE20190660A1 PE20190660A1 PE2019000402A PE2019000402A PE20190660A1 PE 20190660 A1 PE20190660 A1 PE 20190660A1 PE 2019000402 A PE2019000402 A PE 2019000402A PE 2019000402 A PE2019000402 A PE 2019000402A PE 20190660 A1 PE20190660 A1 PE 20190660A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- acid sequence
- region
- fusion protein
- Prior art date
Links
- 108700024845 Hepatitis B virus P Proteins 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 4
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102100021519 Hemoglobin subunit beta Human genes 0.000 abstract 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 abstract 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 241001135569 Human adenovirus 5 Species 0.000 abstract 1
- 241000598171 Human adenovirus sp. Species 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000008488 polyadenylation Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26004—Ribonuclease H (3.1.26.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305909 | 2011-07-12 | ||
| EP12305450 | 2012-04-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20190660A1 true PE20190660A1 (es) | 2019-05-08 |
Family
ID=46506427
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019000402A PE20190660A1 (es) | 2011-07-12 | 2012-07-12 | Mutantes de la polimerasa de hbv |
| PE2014000055A PE20141210A1 (es) | 2011-07-12 | 2012-07-12 | Mutantes de la polimerasa de hbv |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2014000055A PE20141210A1 (es) | 2011-07-12 | 2012-07-12 | Mutantes de la polimerasa de hbv |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9512412B2 (enExample) |
| EP (1) | EP2732034B1 (enExample) |
| JP (1) | JP6189293B2 (enExample) |
| KR (1) | KR102061357B1 (enExample) |
| CN (1) | CN103998604B (enExample) |
| AU (1) | AU2012282506C1 (enExample) |
| BR (1) | BR112014000627B1 (enExample) |
| CA (1) | CA2841890C (enExample) |
| DK (1) | DK2732034T3 (enExample) |
| ES (1) | ES2632497T3 (enExample) |
| HU (1) | HUE033789T2 (enExample) |
| IL (1) | IL230402B (enExample) |
| MX (1) | MX346835B (enExample) |
| PE (2) | PE20190660A1 (enExample) |
| RU (1) | RU2625021C2 (enExample) |
| TW (2) | TWI575070B (enExample) |
| WO (1) | WO2013007772A1 (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5812861B2 (ja) | 2008-08-28 | 2015-11-17 | タイガ バイオテクノロジーズ，インク． | Ｍｙｃの修飾物質、該ｍｙｃの修飾物質を使用する方法、およびｍｙｃを調節する薬剤を同定する方法 |
| TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| JP2015128397A (ja) * | 2014-01-08 | 2015-07-16 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法 |
| WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
| WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
| WO2016167369A1 (ja) * | 2015-04-16 | 2016-10-20 | 国立研究開発法人産業技術総合研究所 | Ｂ型肝炎ウイルス分泌阻害剤 |
| WO2017027350A2 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
| US10538786B2 (en) | 2016-04-13 | 2020-01-21 | Janssen Pharmaceuticals, Inc. | Recombinant arterivirus replicon systems and uses thereof |
| CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
| JOP20190015A1 (ar) | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
| EP3522920A2 (en) | 2016-10-10 | 2019-08-14 | Transgene SA | Immunotherapeutic product and mdsc modulator combination therapy |
| EP3526332B1 (en) | 2016-10-17 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
| AU2017367730A1 (en) * | 2016-12-02 | 2019-06-06 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| CA3045650A1 (en) | 2016-12-05 | 2018-06-14 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
| GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
| KR102658198B1 (ko) | 2017-05-15 | 2024-04-16 | 얀센 백신스 앤드 프리벤션 비.브이. | 안정한 바이러스 함유 조성물 |
| CA3061678A1 (en) | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| CA3085492A1 (en) * | 2017-12-19 | 2019-06-27 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| ES2963179T3 (es) * | 2017-12-19 | 2024-03-25 | Janssen Sciences Ireland Unlimited Co | Vacunas contra el virus de la hepatitis b (VHB) y usos de las mismas |
| BR112020014525A2 (pt) | 2018-01-19 | 2020-12-08 | Janssen Pharmaceuticals, Inc. | Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes |
| IL277128B2 (en) | 2018-03-06 | 2025-11-01 | Precigen Inc | Hepatitis b vaccines and uses of the same |
| BR112020018117A2 (pt) | 2018-03-07 | 2020-12-22 | Transgene | Vírus da pseudovaríola (pcpv), métodos para gerar o pcpv e para amplificar o pcpv, composição, método de tratamento, método para inibir o crescimento de células tumorais, uso ou método e método para induzir ou estimular e/ ou reorientar uma resposta imune |
| US12331076B2 (en) | 2018-10-08 | 2025-06-17 | Janssen Pharmaceuticals, Inc. | Alphavirus-based replicons for administration of biotherapeutics |
| WO2020210231A1 (en) | 2019-04-08 | 2020-10-15 | Taiga Biotechnologies, Inc. | Compositions and methods for the cry opreservation of immune cells |
| CN114072166A (zh) | 2019-05-14 | 2022-02-18 | 泰加生物工艺学公司 | 用于治疗t细胞耗竭的组合物和方法 |
| CA3141003A1 (en) * | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pd-l1 inhibitors |
| WO2020255018A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
| CA3143679A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| EP3986454A1 (en) * | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
| US20220305117A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and hbv-targeting rnai |
| CA3143632A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
| US20220305118A1 (en) * | 2019-06-20 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
| KR20220117627A (ko) * | 2021-02-17 | 2022-08-24 | 주식회사 녹십자 | 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물 |
| CN115851656A (zh) * | 2021-09-24 | 2023-03-28 | 中国科学院生物物理研究所 | 一种乙肝病毒聚合酶的制备方法 |
| CN116333170B (zh) * | 2023-03-28 | 2026-02-17 | 陇东学院 | 一种用于免疫治疗胃癌的重组病毒样纳米颗粒及其应用 |
| JPWO2025022515A1 (enExample) * | 2023-07-24 | 2025-01-30 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2650838A1 (fr) | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
| JP3738395B2 (ja) | 1991-08-26 | 2006-01-25 | エピミューン，インコーポレイティド | Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ |
| EP0687182B1 (en) | 1993-02-26 | 2003-08-06 | The Scripps Research Institute | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| CA2168583C (en) * | 1993-08-02 | 2007-10-02 | Francis V. Chisari | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
| IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| ATE445705T1 (de) | 1995-06-15 | 2009-10-15 | Crucell Holland Bv | Verpackungssysteme für humane rekombinante adenoviren zur gentherapie |
| CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
| JP4492826B2 (ja) | 1996-11-20 | 2010-06-30 | イントロジェン セラピューティクス，インコーポレイテッド | アデノウイルスベクターの産生および精製のための改良された方法 |
| DE69739961D1 (de) | 1996-12-13 | 2010-09-23 | Schering Corp | Methoden zur Virus-Reinigung |
| WO1998056415A1 (en) | 1997-06-11 | 1998-12-17 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| MXPA03006971A (es) * | 2001-02-05 | 2004-05-05 | Stressgen Biotechnologies Corp | Tratamiento del virus de hepatitis b. |
| HU228327B1 (en) | 2001-06-22 | 2013-03-28 | Wistar Inst | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| HU230364B1 (hu) | 2001-11-21 | 2016-03-29 | The Trustees Of The University Of Pennsylvania | Simian adenovírus nukleinsav és aminosav-szekvencia, azt tartalmazó vektorok, és eljárások annak alkalmazására |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| GB0328753D0 (en) | 2003-12-11 | 2004-01-14 | Royal Veterinary College The | Hepatitis B vaccines |
| DK1711518T3 (da) | 2004-01-23 | 2010-04-06 | Angeletti P Ist Richerche Bio | Vaccinebærere for chimpanse-adenovirus |
| CN100339488C (zh) * | 2004-12-07 | 2007-09-26 | 中山大学达安基因股份有限公司 | 乙型肝炎病毒基因组耐药突变检测方法 |
| CN1313483C (zh) * | 2005-12-12 | 2007-05-02 | 浙江大学 | 鸭乙型肝炎病毒多聚酶蛋白ymdd功能区的抑制肽及应用 |
| EP2029169A2 (en) | 2006-06-20 | 2009-03-04 | Transgene S.A. | Recombinant viral vaccine |
| EP2057268B1 (en) | 2006-08-14 | 2014-08-13 | Postech Foundation | A dna vaccine for curing chronic hepatitis b and a method of preparing same |
| KR20080086687A (ko) | 2007-03-23 | 2008-09-26 | 주식회사 파나진 | 라미부딘 내성 ｂ형 간염바이러스 검출을 위한 ρνα프로브, 키트 및 방법 |
| KR20100021603A (ko) | 2007-05-15 | 2010-02-25 | 트랜스진 에스.에이. | 신호전달 펩타이드 |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| ES2618490T3 (es) | 2007-07-03 | 2017-06-21 | Transgene Sa | Estirpes celulares aviares inmortalizadas |
| CN102131920B (zh) | 2007-11-28 | 2013-11-06 | 宾夕法尼亚大学托管会 | 猿猴亚家族C腺病毒SAdV-40、-31和-34及其应用 |
| HRP20170395T1 (hr) | 2007-11-28 | 2017-05-05 | The Trustees Of The University Of Pennsylvania | Podporodice adenovirusa b majmuna sadv-28, 27,-29,-32,-33, i -35 i njihove primjene |
| EP3128010A1 (en) | 2007-11-28 | 2017-02-08 | The Trustees Of The University Of Pennsylvania | Simian subfamily e adenoviruses sadv-30 and uses thereof |
| EP2325298B1 (en) | 2008-03-04 | 2016-10-05 | The Trustees Of The University Of Pennsylvania | SIMIAN ADENOVIRUSES SAdV-36, -42.1, -42.2, AND -44 AND USES THEREOF |
| AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
| KR20120026526A (ko) | 2009-05-12 | 2012-03-19 | 트랜스진 에스.에이. | 불멸화 조류 세포주 및 그의 용도 |
| WO2011001565A1 (ja) | 2009-07-01 | 2011-01-06 | シャープ株式会社 | 液晶表示素子及び液晶表示装置 |
| KR20120052352A (ko) * | 2009-08-07 | 2012-05-23 | 트랜스진 에스.에이. | Ｈｂｖ 감염을 치료하는 조성물 |
| TWI575070B (zh) * | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Ｈｂｖ聚合酶突變體 |
-
2012
- 2012-07-11 TW TW101124905A patent/TWI575070B/zh active
- 2012-07-11 TW TW105141433A patent/TWI623618B/zh active
- 2012-07-12 US US14/232,082 patent/US9512412B2/en not_active Expired - Fee Related
- 2012-07-12 JP JP2014519553A patent/JP6189293B2/ja not_active Expired - Fee Related
- 2012-07-12 WO PCT/EP2012/063640 patent/WO2013007772A1/en not_active Ceased
- 2012-07-12 RU RU2014104360A patent/RU2625021C2/ru active
- 2012-07-12 BR BR112014000627-0A patent/BR112014000627B1/pt not_active IP Right Cessation
- 2012-07-12 PE PE2019000402A patent/PE20190660A1/es unknown
- 2012-07-12 DK DK12733748.3T patent/DK2732034T3/en active
- 2012-07-12 CN CN201280044383.1A patent/CN103998604B/zh active Active
- 2012-07-12 ES ES12733748.3T patent/ES2632497T3/es active Active
- 2012-07-12 CA CA2841890A patent/CA2841890C/en active Active
- 2012-07-12 EP EP12733748.3A patent/EP2732034B1/en active Active
- 2012-07-12 KR KR1020147003482A patent/KR102061357B1/ko not_active Expired - Fee Related
- 2012-07-12 HU HUE12733748A patent/HUE033789T2/en unknown
- 2012-07-12 MX MX2014000488A patent/MX346835B/es active IP Right Grant
- 2012-07-12 PE PE2014000055A patent/PE20141210A1/es active IP Right Grant
- 2012-07-12 AU AU2012282506A patent/AU2012282506C1/en not_active Ceased
-
2014
- 2014-01-12 IL IL230402A patent/IL230402B/en active IP Right Grant
-
2016
- 2016-12-05 US US15/369,118 patent/US10190105B2/en active Active
-
2019
- 2019-01-25 US US16/257,784 patent/US10662414B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20190660A1 (es) | Mutantes de la polimerasa de hbv | |
| AU2015208247B2 (en) | Muscle-specific nucleic acid regulatory elements and methods and use thereof | |
| CN102666575B (zh) | 分枝杆菌疫苗 | |
| JP7269806B2 (ja) | 結核組成物及びそれを使用する方法 | |
| CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
| FI3256579T3 (fi) | Kysteiiniproteaasi | |
| MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
| AU2022241594B2 (en) | Improved lamp constructs | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| NZ603348A (en) | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof | |
| JP2018506286A5 (enExample) | ||
| HRP20231183T1 (hr) | Optimizirani gen faktora viii | |
| SG10201901482XA (en) | Oncolytic adenovirus encoding a b7 protein | |
| TN2011000558A1 (en) | Improved reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c) | |
| WO2013151672A3 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
| EP3939606A3 (en) | Improved methods and compounds for eliminating immune responses to therapeutic agents | |
| CY1118861T1 (el) | Αναγνωριση εξω-κυτταρικης μορφης του ρτεν που μπορει να χρησιμοποιηθει για την θεραπεια ογκων | |
| CN106103471A (zh) | 异源寡聚分枝杆菌抗原的融合 | |
| AU2019346549B2 (en) | Compositions and methods for the treatment of Netherton Syndrome | |
| RU2019104948A (ru) | Генетически модифицированные бактерии, стабильно экспрессирующие ил-10 и инсулин | |
| US20140234316A1 (en) | Vaccibodies targeted to cross-presenting dendritic cells | |
| EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
| WO2015165480A1 (en) | Human cytomegalovirus vaccine compositions and method of producing the same | |
| Wang et al. | Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus | |
| MX2018013177A (es) | Proteina de fusion que contiene variante ccl3 y uso de la misma referencia cruzada para aplicaciones relacionadas. |